News Updates
J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion | CNBC
Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies.
Science Corporation raises $400M to commercialize BCI device | MedTechDive
The device, which Science has launched in Europe, is designed to restore the sight of people with some forms of vision loss.
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet | Reuters
Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers.
AI drugmaker Isomorphic restocks with $5B fundraise | BioPharmaDive
Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
White House pulls nomination of Heidi Overton to lead FDA | TheHill
The White House withdrew the nomination of Heidi Overton to lead the Food and Drug Administration (FDA) amid opposition from Senate Republicans, it confirmed to The Hill.
Chinese biotech competition and the payer squeeze are reshaping European biotech | Labiotech
At BIO-Europe last week one preclinical company explained how it was building its drug development program with a focus on fitting prescribing and reimbursement models.
Isomorphic Labs breaks biotech VC fundraising record with $5B series C | BioSpace
After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna | FierceBiotech
Pfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.
|